Stay updated on LAG-3 in GBM: Alone & with Nivolumab Clinical Trial
Sign up to get notified when there's something new on the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page.

Latest updates to the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a Phase I trial involving anti-LAG-3 and anti-CD137 treatments for recurrent glioblastoma, while adding new identifiers and collaborators related to the study.SummaryDifference42%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
Stay in the know with updates to LAG-3 in GBM: Alone & with Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page.